Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending August 13, 2007. The report serves as a notification of transactions involving directors and persons discharging managerial responsibility, specifically regarding the US Retirement Savings Plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on a specific transaction event rather than comprehensive financial performance.
Material Changes
The filing details a re-valuation of the cash element of the notional investment held within the US Retirement Savings Plan, which is notionally held in GSK Ordinary Share ADRs. On August 10, 2007, an increase in the notional allocation of Ordinary Share ADRs occurred at a price of $52.06 per ADR share. The specific allocations were:
- Mrs C Bruck Slaoui: 3 ADRs
- Dr R G Greig: 1 ADR
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It is a compliance notification pursuant to Disclosure and Transparency Rules 3.1.4R(1)(a) and 3.1.4R(1)(b).
Investor Verification Points
- Verify the accuracy of the $52.06 per ADR share price used for the notional allocation on August 10, 2007.
- Confirm the specific number of ADRs allocated to Mrs C Bruck Slaoui (3) and Dr R G Greig (1).
- Ensure the transaction was properly notified to the Administrators of the Plan and the registrant on August 13, 2007.